Benzinga | Dec 10, 2021 08:37AM EST

Benchmark Initiates Coverage On Spruce Biosciences with Speculative Buy Rating, Announces Price Target of $7

Benchmark analyst Aydin Huseynov initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Speculative Buy rating and announces Price Target of $7.